# mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

> **NCT05412589** · PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 35 (estimated)

## Conditions studied

- Stage III Hepatocellular Cancer (CNLC Staging)

## Interventions

- **DRUG:** mFOLFOX7+Camrelizumab+Apatinib

## Key facts

- **NCT ID:** NCT05412589
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-10
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05412589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05412589, "mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05412589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*